Literature DB >> 10454504

AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor.

B W Griffin1, P Klimko, J Y Crider, N A Sharif.   

Abstract

A novel analog of prostaglandin F(2alpha) [AL-8810; (5Z, 13E)-(9S, 11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19, 20-pentanor-5,13-prostadienoic acid] has been discovered with uniquely low efficacy (E(max)) at the endogenous prostaglandin F(2alpha) receptors (FP receptors) of A7r5 rat thoracic aorta smooth muscle cells and Swiss mouse 3T3 fibroblasts, as assayed by stimulation of phospholipase C activity. AL-8810 has weak agonist potency (EC(50)) of 261 +/- 44 nM (n = 3) and E(max) = 19% (relative to the full FP receptor agonist cloprostenol) in A7r5 cells and EC(50) of 186 +/- 63 nM (n = 3) and E(max) = 23% in 3T3 fibroblasts. AL-8810 exhibited properties of an apparent competitive antagonist, i.e., produced parallel dextral shifts of the agonist concentration-response curves and no significant suppression of the maximal agonist-induced response, when the potent, selective FP receptor agonist fluprostenol was used. The inhibition parameters of AL-8810 were: pA(2) = 6.68 +/- 0.23 and 6.34 +/- 0.09 (n = 3-4) for A7r5 cells and 3T3 cells, respectively, with Schild slopes ranging from 0.80 to 0.92. AL-8810 concentration-dependently antagonized the response to 100 nM fluprostenol (K(i) = 426 +/- 63 nM; n = 5) in A7r5 cells. However, even at 10 microM concentration, AL-8810 did not significantly inhibit functional responses of TP, DP, EP(2), EP(4), receptor subtypes in various cell lines. AL-8810 also did not antagonize the phospholipase C-coupled V(1)-vasopressin receptor in A7r5 cells. These results suggest that AL-8810 is a unique, selective antagonist at the FP receptor, a heretofore unavailable pharmacological tool that should be valuable for studying FP receptor-mediated functional responses in complex biological systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454504

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

1.  Pharmacological characterization of prostanoid receptors mediating vasoconstriction in human umbilical vein.

Authors:  Federico Manuel Daray; Ana Itatí Minvielle; Soledad Puppo; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

2.  Effects of progesterone on motility and prostaglandin levels in the distal guinea pig colon.

Authors:  Zuo Liang Xiao; Piero Biancani; Jose Behar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

3.  Cyclic AMP-mediated chloride secretion is induced by prostaglandin F2alpha in human isolated colon.

Authors:  D Collins; A M Hogan; M M Skelly; A W Baird; D C Winter
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 4.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

5.  Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.

Authors:  D F Woodward; A H Krauss; J W Wang; C E Protzman; A L Nieves; Y Liang; Y Donde; R M Burk; K Landsverk; C Struble
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

6.  Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells.

Authors:  Luigia Di Francesco; Melania Dovizio; Annalisa Trenti; Emanuela Marcantoni; Ashleigh Moore; Peadar O'Gaora; Cathal McCarthy; Stefania Tacconelli; Annalisa Bruno; Sara Alberti; Salvatore Gizzo; Giovanni Battista Nardelli; Genny Orso; Orina Belton; Lucia Trevisi; Dan A Dixon; Paola Patrignani
Journal:  Br J Pharmacol       Date:  2015-08-03       Impact factor: 8.739

7.  Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.

Authors:  Toru Oga; Toshiyuki Matsuoka; Chengcan Yao; Kimiko Nonomura; Shiho Kitaoka; Daiji Sakata; Yoshihiro Kita; Kiminobu Tanizawa; Yoshio Taguchi; Kazuo Chin; Michiaki Mishima; Takao Shimizu; Shuh Narumiya
Journal:  Nat Med       Date:  2009-11-29       Impact factor: 53.440

Review 8.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

9.  Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase.

Authors:  Ko Fujimori; Toshiyuki Ueno; Nanae Nagata; Kaori Kashiwagi; Kosuke Aritake; Fumio Amano; Yoshihiro Urade
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

10.  Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway.

Authors:  Kurt J Sales; David Maldonado-Pérez; Vivien Grant; Rob D Catalano; Martin R Wilson; Pamela Brown; Alistair R W Williams; Richard A Anderson; E Aubrey Thompson; Henry N Jabbour
Journal:  Biochim Biophys Acta       Date:  2009-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.